NextWave Pharmaceuticals Inc.

NextWave Pharmaceuticals Inc. is a pharmaceutical company focused on developing and commercializing innovative treatments primarily for Attention Deficit Hyperactivity Disorder (ADHD). Their portfolio includes specialized medications designed to enhance patient care and medication adherence. NextWave Pharmaceuticals Inc.

, founded in 2005, is headquartered in Cupertino, US. The company was established to create effective ADHD treatments and has completed a total of 6 deals. In October 2012, NextWave was acquired by Pfizer Inc. for USD 255 mn, with potential additional payments of USD 425 mn contingent on sales benchmarks being achieved.

NextWave Pharmaceuticals specializes in the development and commercialization of innovative pharmaceutical products aimed primarily at treating Attention Deficit Hyperactivity Disorder (ADHD). Their flagship product, Quillivant XR® (methylphenidate HCl), is a liquid central nervous system stimulant designed for consistent medication delivery throughout the day, specifically formulated for pediatric patients aged 6 and older. Quillivant XR addresses key behavioral challenges faced by children with ADHD and is marketed primarily in the United States, with potential expansion into other international markets, targeting healthcare providers and caregivers. NextWave Pharmaceuticals generates revenue mainly through sales of its prescription medication, Quillivant XR.

The revenue model relies on partnerships with healthcare providers, ensuring the medication is prescribed directly to patients. Revenue stems from direct sales to pharmacies and healthcare facilities, with pricing determined through negotiations with pharmacy benefit managers and insurance companies. As a federally controlled substance, Quillivant XR is distributed under strict regulatory guidelines, highlighting the company's focus on compliance. They also have co-pay offers for eligible patients to make the treatment more accessible.

Following their acquisition by Pfizer in October 2012, NextWave Pharmaceuticals plans to leverage recent funding of USD 680 mn from the trade sale to expand its product offerings and geographic reach. Future initiatives include developing new ADHD treatment options and penetrating international markets with a focus on Europe and Asia by 2024. The funding will support research and development of upcoming products, ensuring they meet market needs and regulatory standards.